adrenochrome

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{About|the chemical compound|the Sisters of Mercy song|Some Girls Wander by Mistake}}

{{Use dmy dates|date=January 2022}}

{{chembox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 477243063

| Name = Adrenochrome

| ImageFile = Adrenochrome.svg

| ImageClass = skin-invert-image

| ImageSize = 170

| ImageAlt = Structural formula of adrenochrome

| ImageFile1 = Adrenochrome 3D ball.png

| ImageSize1 = 170

| ImageAlt1 = Ball-and-stick model of the adrenochrome molecule

| IUPACName = 3-Hydroxy-1-methyl-2,3-dihydro-1H-indole-5,6-dione

| OtherNames = Adraxone; Pink adrenaline

| Section1 = {{Chembox Identifiers

| index_label = (racemic)

| index1_label = (R)-Enantiomer

| index2_label = (S)-Enantiomer

| ChEMBL = 1314174

| ChEBI = 166544

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 5687

| EINECS = 200-192-8

| InChI = 1/C9H9NO3/c1-10-4-9(13)5-2-7(11)8(12)3-6(5)10/h2-3,9,13H,4H2,1H3

| InChIKey = RPHLQSHHTJORHI-UHFFFAOYAD

| PubChem = 5898

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C9H9NO3/c1-10-4-9(13)5-2-7(11)8(12)3-6(5)10/h2-3,9,13H,4H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = RPHLQSHHTJORHI-UHFFFAOYSA-N

| CASNo_Ref = {{cascite|correct|CAS}}

| CASNo = 54-06-8

| CASNo1 = 7506-92-5

| CASNo2 = 5181-82-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 70G54NQL71

| SMILES = O=C1\C=C2/C(=C\C1=O)N(CC2O)C

}}

| Section2 = {{Chembox Properties

| Appearance = deep-violet{{cite journal |last1=Heacock |first1=R. A. |last2=Nerenberg |first2=C. |last3=Payza |first3=A. N. |title=The Chemistry of the "Aminochromes": Part I. The Preparation and Paper Chromatography of Pure Adrenochrome |journal=Canadian Journal of Chemistry |date=1 May 1958 |volume=36 |issue=5 |pages=853–857 |doi=10.1139/v58-124 |doi-access=free }}

| C=9|H=9|N=1|O=3

| Density = 3.785 g/cm3

| BoilingPtC = 115-120

| BoilingPt_notes = (decomposes)

}}

}}

Adrenochrome is a chemical compound produced by the oxidation of adrenaline (epinephrine). It was the subject of limited research from the 1950s through to the 1970s as a potential cause of schizophrenia. While it has no current medical application, the semicarbazide derivative, carbazochrome, is a hemostatic medication.

Despite this compound's name, it is unrelated to the element chromium; instead, the ‑chrome suffix indicates a relationship to color, as pure adrenochrome has a deep violet color.

Chemistry

The oxidation reaction that converts adrenaline into adrenochrome occurs both in vivo and in vitro. Silver oxide (Ag2O) was among the first reagents employed for this,{{cite journal |last1=Veer |first1=W. L. C. |title=Melanin and its precursors II. On adrenochrome |journal=Recueil des Travaux Chimiques des Pays-Bas |date=1942 |volume=61 |issue=9 |pages=638–646 |doi=10.1002/recl.19420610904}} but a variety of other oxidizing agents have been used successfully.{{cite journal |last1=Heacock |first1=R. A. |title=The Chemistry Of Adrenochrome And Related Compounds |journal=Chemical Reviews |date=1 April 1959 |volume=59 |issue=2 |pages=181–237 |doi=10.1021/cr50026a001 |url=https://chemistry.mdma.ch/hiveboard/rhodium/pdf/adrenochrome.review.pdf}} In solution, adrenochrome is pink and further oxidation of the compound causes it to polymerize into brown or black melanin compounds.

= Synthesis =

Adrenochrome is readily synthesized from commercially available reagents: chloroacetic acid and catechol react in the presence of phosphoryl chloride to yield chloroacetylcatechol. After purification, chloroacetylcatechol is reacted with aqueous methylamine and treated with hydrochloric acid, yielding adrenalone hydrochloride. This is then hydrogenated to racemic adrenaline. Finally, adrenaline is oxidized to adrenochrome by an appropriate oxidizing agent such as silver oxide.{{cite journal|url=https://pubs.acs.org/doi/10.1021/ja01129a531|title=Synthesis of dl-Adrenalin-β-C14 and dl-Adrenochrome-β-C14|publisher=ACS Publications|author=Schayer, Richard W.|journal=Journal of the American Chemical Society |language=en-US|url-status=live|date=1952|volume=74 |issue=9 |page=2441 |doi=10.1021/ja01129a531 |bibcode=1952JAChS..74.2441S |access-date=October 25, 2022|archivedate=October 25, 2022|archiveurl=https://archive.today/20221025141335/https://pubs.acs.org/doi/10.1021/ja01129a531|url-access=subscription}}

History

File:Adrenochrome.jpg

Several small-scale studies involving 15 or fewer test subjects conducted in the 1950s and 1960s reported that adrenochrome triggered psychotic reactions such as thought disorder and derealization.{{cite journal | last1 = Smythies | first1 = John | author-link1 = John Raymond Smythies | s2cid = 37594882 | title = The adrenochrome hypothesis of schizophrenia revisited | journal = Neurotoxicity Research | volume = 4 | issue = 2 | pages = 147–150 | date = January 2002 | pmid = 12829415 | doi = 10.1080/10298420290015827 | citeseerx = 10.1.1.688.3796 | issn = 1029-8428 | eissn = 1476-3524 | oclc = 50166444 }}

In 1954, researchers Abram Hoffer and Humphry Osmond claimed that adrenochrome is a neurotoxic, psychotomimetic substance and may play a role in schizophrenia and other mental illnesses.{{cite journal | last1 = Hoffer | first1 = Abram | author-link1 = Abram Hoffer | last2 = Osmond | first2 = Humphrey | author-link2 = Humphry Osmond | first3 = John | last3 = Smythies| author-link3 = John Raymond Smythies | title = Schizophrenia: A New Approach. II. Result of a Year's Research | journal = The Journal of Mental Science | volume = 100 | issue = 418 | pages = 29–45 | date = January 1954 | pmid = 13152519 | doi = 10.1192/bjp.100.418.29 | eissn = 1472-1465 | issn = 0007-1250 | lccn = 89649366 | oclc = 1537306 | s2cid = 42531852 | df = dmy-all }} In what Hoffer called the "adrenochrome hypothesis",{{cite journal | last1 = Hoffer | first1 = Abram | author-link1 = Abram Hoffer | last2 = Osmond | first2 = Humphrey | author-link2 = Humphry Osmond | title = The Adrenochrome Hypothesis and Psychiatry | url = http://www.orthomolecular.org/library/jom/1999/articles/1999-v14n01-p049.shtml | access-date = 2024-03-15 | journal = The Journal of Orthomolecular Medicine | volume = 14 | issue = 1 | date = First Quarter 1999 | pages = 49–62 | archive-url = https://web.archive.org/web/20240220043758/http://www.orthomolecular.org/library/jom/1999/articles/1999-v14n01-p049.shtml | archive-date = 2024-02-20 | url-status = live | issn = 0834-4825 | oclc = 15726974 | s2cid = 41468628 | df = dmy-all}} he and Osmond in 1967 speculated that megadoses of vitamin C and niacin could cure schizophrenia by reducing brain adrenochrome.{{cite book | author1=Abram Hoffer | author2=Humphrey Osmond | title=The Hallucinogens | publisher=Elsevier | date=1967 | isbn=978-1-4832-3296-6 | doi=10.1016/c2013-0-12543-3 | lccn=66030086 | oclc=332437 | ol=OL35255701M | url=https://bitnest.netfirms.com/external/Books/TheHallucinogens | pages=272–273}}{{cite journal | vauthors = Hoffer A | date = 1994 | title = Schizophrenia: An Evolutionary Defense Against Severe Stress | journal = Journal of Orthomolecular Medicine | volume = 9 | issue = 4 | pages = 205–2221 | url = http://orthomolecular.org/library/jom/1994/pdf/1994-v09n04-p205.pdf }}

The treatment of schizophrenia with such potent anti-oxidants is controversial. In 1973, the American Psychiatric Association reported methodological flaws in Hoffer's work on niacin as a schizophrenia treatment and referred to follow-up studies that did not confirm any benefits of the treatment.{{cite web | vauthors = Lipton MA, Ban TA, Kane FJ, Levine J, Mosher LR, Wittenborn R | title = Task Force Report on Megavitamin and Orthomolecular Therapy in Psychiatry | publisher = American Psychiatric Association | year = 1973 | url = https://www.old.quackwatch.org/01QuackeryRelatedTopics/apa_megavitamin.pdf | access-date = 7 September 2020 | archive-date = 23 February 2021 | archive-url = https://web.archive.org/web/20210223194022/https://www.old.quackwatch.org/01QuackeryRelatedTopics/apa_megavitamin.pdf | url-status = dead }} Multiple additional studies in the United States,{{cite journal | doi = 10.1001/archpsyc.1973.01750330010002 |vauthors=Wittenborn JR, Weber ES, Brown M | title = Niacin in the Long-Term Treatment of Schizophrenia | journal = Archives of General Psychiatry | year = 1973 | volume = 28 | issue = 3 | pages = 308–315 | pmid = 4569673 | url = http://archpsyc.ama-assn.org/cgi/content/abstract/28/3/308| url-access = subscription }} Canada,{{cite journal | vauthors = Ban TA, Lehmann HE | title = Nicotinic Acid in the Treatment of Schizophrenia: A Summary Report | journal = Schizophrenia Bulletin | year = 1970 | volume = 1 | issue = 3 | pages = 5–7 | doi = 10.1093/schbul/1.3.5 | doi-access = free }} and Australia{{cite journal |vauthors=Vaughan K, McConaghy N | s2cid = 38857700 | title = Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial | journal = Australian and New Zealand Journal of Psychiatry | year = 1999 | volume = 33 | issue = 1 | pages = 84–88 | pmid = 10197889 | doi =10.1046/j.1440-1614.1999.00527.x}} similarly failed to find benefits of megavitamin therapy to treat schizophrenia.

The adrenochrome theory of schizophrenia waned, despite some evidence that it may be psychotomimetic, as adrenochrome was not detectable in people with schizophrenia.{{citation needed|date=March 2021}}

In the early 2000s, interest was renewed by the discovery that adrenochrome may be produced normally as an intermediate in the formation of neuromelanin. This finding may be significant because adrenochrome is detoxified at least partially by glutathione-S-transferase. Some studies have found genetic defects in the gene for this enzyme.{{cite book | vauthors = Smythies J | veditors = Smythies J |title=Disorders of Synaptic Plasticity and Schizophrenia |date=2004 |publisher=Elsevier Academic Press |isbn=978-0-12-366860-8 |pages=xv |edition=1st}}

Adrenochrome is also believed to have cardiotoxic properties.{{cite journal |last1=Bindoli |first1=Alberto |last2=Rigobello |first2=Maria Pia |last3=Galzigna |first3=Lauro |title=Toxicity of aminochromes |journal=Toxicology Letters |date=July 1989 |volume=48 |issue=1 |pages=3–20 |doi=10.1016/0378-4274(89)90180-X|pmid=2665188 |hdl=11577/2475305 |hdl-access=free }}{{cite journal |last1=Behonick |first1=George S. |last2=Novak |first2=Mark J. |last3=Nealley |first3=Eric W. |last4=Baskin |first4=Steven I. |title=Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes) |journal=Journal of Applied Toxicology |date=December 2001 |volume=21 |issue=S1 |pages=S15–S22 |doi=10.1002/jat.793|pmid=11920915 |s2cid=27865845 }}

See also

References

{{reflist}}